Rockefeller Capital Management
DSGN icon

Rockefeller Capital Management’s Design Therapeutics DSGN Stock Holding History

Rockefeller Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.2K Buy
3,684
+2,946
+399% +$29.8K ﹤0.01% 3405
2025
Q4 		$6.92K Buy
+738
New +$5.78K ﹤0.01% 3954
2023
Q1 		– Sell
-61
Closed – – 2472
2022
Q4 		$0 Hold
61
– – ﹤0.01% 3920
2022
Q3 		$1K Hold
61
– – ﹤0.01% 3697
2022
Q2 		$0 Buy
+61
New +$824 ﹤0.01% 4162

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Rockefeller Capital Management's DSGN Position: Q1 2026 in Review

Rockefeller Capital Management increased its Design Therapeutics (DSGN) stake by 399% in Q1 2026, buying an estimated $29.8K and bringing the position to 3,684 shares worth $39.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3405.

Rockefeller Capital Management first reported a position in DSGN in Q2 2022 and has held it in 5 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Rockefeller Capital Management held 3,684 shares of Design Therapeutics worth $39.2K as of Q1 2026.
  • Rockefeller Capital Management bought 2,946 Design Therapeutics shares in Q1 2026, an estimated $29.8K.
  • Design Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3405 holding.
  • Rockefeller Capital Management first reported a position in Design Therapeutics in Q2 2022 and has held it in 5 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.